or Try an Advanced Search...

    Technical Analysis for GNLX - Genelux Corporation

    Grade Last Price % Change Price Change
    F 3.60 -1.10% -0.04
    GNLX closed down 1.1 percent on Thursday, May 16, 2024, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical GNLX trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Crossed Above 20 DMA Bullish -1.10%
    Inside Day Range Contraction -1.10%
    Wide Bands Range Expansion -1.10%
    Fell Below 20 DMA Bearish 0.56%
    Outside Day Range Expansion 0.56%
    Wide Bands Range Expansion 0.56%
    Down 3 Days in a Row Weakness 0.56%
    Older End-of-Day Signals for GNLX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 4 hours ago
    Down 3% about 7 hours ago
    60 Minute Opening Range Breakdown about 7 hours ago
    20 DMA Support about 7 hours ago
    Fell Below Previous Day's Low about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GNLX Chart by TradingView
    Basic chart:

    Profile

    Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Virotherapy Immunotherapies Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Oncolytic Virus Experimental Cancer Treatments Transgene Sa Treatment Of Ovarian Cancer Treatment Of Pancreatic Cancer

    Is GNLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 10 Genelux GAAP EPS of -$0.29 misses by $0.06
    May 9 Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
    May 5 Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders
    Apr 26 Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
    Apr 23 Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
    Apr 5 After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
    Apr 4 All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
    Apr 1 Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Feb 2 Genelux files for a $300M mixed securities shelf
    Dec 15 Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)
    See more GNLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 40.98
    52 Week Low 3.06
    Average Volume 119,366
    200-Day Moving Average 13.50
    50-Day Moving Average 4.66
    20-Day Moving Average 3.58
    10-Day Moving Average 3.74
    Average True Range 0.39
    RSI (14) 41.86
    ADX 24.57
    +DI 14.86
    -DI 21.78
    Chandelier Exit (Long, 3 ATRs) 3.04
    Chandelier Exit (Short, 3 ATRs) 4.24
    Upper Bollinger Bands 4.11
    Lower Bollinger Band 3.05
    Percent B (%b) 0.52
    BandWidth 29.70
    MACD Line -0.27
    MACD Signal Line -0.38
    MACD Histogram 0.1063
    Fundamentals Value
    Market Cap 96.18 Million
    Num Shares 26.7 Million
    EPS -1.06
    Price-to-Earnings (P/E) Ratio -3.40
    Price-to-Sales 1003.60
    Price-to-Book 10.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.84
    Resistance 3 (R3) 3.83 3.75 3.80
    Resistance 2 (R2) 3.75 3.69 3.75 3.79
    Resistance 1 (R1) 3.67 3.65 3.63 3.68 3.77
    Pivot Point 3.59 3.59 3.57 3.59 3.59
    Support 1 (S1) 3.51 3.53 3.47 3.52 3.43
    Support 2 (S2) 3.43 3.49 3.43 3.41
    Support 3 (S3) 3.35 3.43 3.40
    Support 4 (S4) 3.36